PhD Scientific Days 2025

Poster Session I. - D: Pathological and Oncological Sciences

Ivermectin Inhibits HSPB1 Phosphorylation and Improves Efficacy of Modulated Electro-hyperthermia in Mouse Breast Cancer Isografts

Előadó neve

Dr. Aloss Kenan

Neptun code

UL1GAP

Előadó munkahelye

Department of Pharmacology and Pharmacotherapy-Semmelweis University

Előadó telefonszáma

+36302411221

Előadó e-mail címe

kenan.aloss@hotmail.com

Az előadás címe

Ivermectin Inhibits HSPB1 Phosphorylation and Improves Efficacy of Modulated Electro-hyperthermia in Mouse Breast Cancer Isografts

Szerző(k) neve és munkahelye

Kenan Aloss^1,2, Pedro Henrique Leroy Viana², Nino Giunashvili², Syeda Mahak Zahra Bokhari², Csaba András Schvarcz², Peter Hamar²

1: Department of Pharmacology and Pharmacotherapy, Semmelweis University
2: Institute of Translational Medicine, Semmelweis University

Bemutatás módja

Poszter

Szekció

Poster Session I. - D: Pathological and Oncological Sciences

Language of the presentation

English

Preferred session

Pathological and Oncological Sciences

Összefoglaló szövege

Introduction
Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype with limited treatment options. Modulated electro-hyperthermia (mEHT) is a novel adjuvant cancer therapy, that induces selective cancer damage. However, mEHT upregulates heat shock protein beta 1 (HSPB1), a cancer-promoting stress chaperone molecule.
Aim:
we investigated whether ivermectin (IVM), an anthelminthic drug, may synergize with mEHT and enhance its anti-cancer effects by inhibiting HSPB1 phosphorylation.
Methods:
Isogenic 4T1 TNBC cells were inoculated into Balb/C mice and treated with mEHT, IVM, or a combination of both. The tumor size was measured by ultrasound and digital caliper. Protein localization and expression were evaluated by immunohistochemistry and western blot, respectively.
Results:
The mEHT+IVM combination was more effective at inhibiting tumor growth than mEHT or IVM monotherapies. Furthermore, IVM downregulated the phosphorylated form of mEHT-induced HSPB1. Consequently, a combination of mEHT and IVM caused the strongest cancer tissue damage, associated with the strongest pro-apoptotic and anti-proliferative effects. In addition, there was no significant body weight loss in mice treated with mEHT and IVM, indicating that this combination was well-tolerated.
Conclusion:
mEHT combined with IVM is a new, effective, and safe option for the treatment of TNBC.
Funding:
EKÖP-2024-92

University

Semmelweis University

Supervisor

Peter Hamar

Publication of my abstract

I give consent to the publication of my abstract on the website of the congress.

phd.section.field

after finishing doctoral studies with absolutorium (PhD)

Kind

Szabad

Status

elfogadva

Accepted presentation method

poszter

Előadás fájl jóváhagyás

nem rendelkezett róla

Előadó

6828

Start

16:30

End

16:36